NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, Forecast & News

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $1.62 million for the quarter. View NovaBay Pharmaceuticals' Earnings History.

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$6-8 million, compared to the consensus revenue estimate of $$7.65 million.

3 brokerages have issued 1-year price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $1.10. On average, they expect NovaBay Pharmaceuticals' stock price to reach $1.10 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.

Media stories about NBY stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 513,700 shares, a decline of 18.1% from the December 15th total of 627,200 shares. Based on an average daily volume of 528,200 shares, the short-interest ratio is presently 1.0 days. Approximately 3.2% of the shares of the stock are short sold. View NovaBay Pharmaceuticals' Current Options Chain.

Some companies that are related to NovaBay Pharmaceuticals include Pediapharm (PDP), 4d Pharma (DDDD), Promis Neurosciences (PMN), Verona Pharma (VRP), IntelGenx Technologies (IGX), Tiziana Life Sciences (TILS), Emerald Health Therapeutics (EMH), Protalix Biotherapeutics (PLX), Asterias Biotherapeutics (AST), ReNeuron Group (RENE), Covalon Technologies (COV), Zelda Therapeutics (ZLD), AquaBounty Technologies (AQB), Nuformix (NFX) and Actinium Pharmaceuticals (ATNM).

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Opko Health (OPK), Achillion Pharmaceuticals (ACHN), AEterna Zentaris (AEZS), Catalyst Pharmaceuticals (CPRX), CorMedix (CRMD), SLS International (SLS), Arbutus Biopharma (ABUS), Agenus (AGEN), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBY stock can currently be purchased for approximately $0.63.

NovaBay Pharmaceuticals has a market capitalization of $17.53 million. NovaBay Pharmaceuticals employs 70 workers across the globe.View Additional Information About NovaBay Pharmaceuticals.

The official website for NovaBay Pharmaceuticals is http://novabay.com/.

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.